PE20121537A1 - COMBINATION OF THEOBROMINE WITH A DECONGESTIVE - Google Patents

COMBINATION OF THEOBROMINE WITH A DECONGESTIVE

Info

Publication number
PE20121537A1
PE20121537A1 PE2012000813A PE2012000813A PE20121537A1 PE 20121537 A1 PE20121537 A1 PE 20121537A1 PE 2012000813 A PE2012000813 A PE 2012000813A PE 2012000813 A PE2012000813 A PE 2012000813A PE 20121537 A1 PE20121537 A1 PE 20121537A1
Authority
PE
Peru
Prior art keywords
decongestive
theobromine
combination
composition
synphrine
Prior art date
Application number
PE2012000813A
Other languages
Spanish (es)
Inventor
John Brew
Robin Mark Bannister
Original Assignee
Biocopea Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocopea Ltd filed Critical Biocopea Ltd
Publication of PE20121537A1 publication Critical patent/PE20121537A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE TEOBROMINA Y UN AGENTE DESCONGESTIVO TAL COMO PSEUDOEFEDRINA, EFEDRINA, NAFAZOLINA, FENILEFRINA, SINEFRINA, ENTRE OTROS. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE LA TOSREFERRING TO A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEOBROMINE AND A DECONGESTIVE AGENT SUCH AS PSEUDOEPHEDRINE, EPHEDRINE, NAFAZOLINE, PHENYLPHRINE, SYNPHRINE, AMONG OTHERS. SUCH COMPOSITION IS USEFUL IN THE TREATMENT OF COUGH

PE2012000813A 2009-12-14 2010-12-14 COMBINATION OF THEOBROMINE WITH A DECONGESTIVE PE20121537A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0921805.8A GB0921805D0 (en) 2009-12-14 2009-12-14 Drug composition and its use in therapy

Publications (1)

Publication Number Publication Date
PE20121537A1 true PE20121537A1 (en) 2012-12-21

Family

ID=41667045

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000813A PE20121537A1 (en) 2009-12-14 2010-12-14 COMBINATION OF THEOBROMINE WITH A DECONGESTIVE

Country Status (19)

Country Link
EP (1) EP2512464A1 (en)
JP (2) JP2013513651A (en)
CN (2) CN105816462A (en)
AU (1) AU2010332494B2 (en)
BR (1) BR112012014161A2 (en)
CA (1) CA2784214C (en)
CO (1) CO6541630A2 (en)
EC (1) ECSP12012132A (en)
GB (1) GB0921805D0 (en)
IL (1) IL220383A (en)
MX (1) MX343222B (en)
NZ (1) NZ600243A (en)
PE (1) PE20121537A1 (en)
PH (1) PH12012501203A1 (en)
RU (1) RU2564904C2 (en)
SG (2) SG10201408377QA (en)
UA (1) UA105944C2 (en)
WO (1) WO2011073646A1 (en)
ZA (1) ZA201204293B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9314465B2 (en) 2009-06-16 2016-04-19 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
GB0910375D0 (en) 2009-06-16 2009-07-29 Biocopea Ltd Drug composition and its use in therapy
GB201111485D0 (en) * 2011-07-05 2011-08-17 Biocopea Ltd Drug composition and its use in therapy
US10016437B2 (en) 2009-06-16 2018-07-10 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
US9308211B2 (en) 2009-06-16 2016-04-12 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007103A1 (en) * 1993-09-07 1995-03-16 The Procter & Gamble Company Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive
HUP9700654A2 (en) * 1997-03-26 1999-09-28 Dezső Korbonits Antitussive compositions containing theobromine
US6417206B1 (en) * 2001-01-26 2002-07-09 Medpointe Healthcare Inc. Antitussive/antihist aminic/decongestant compositions
JP2002308761A (en) * 2001-04-09 2002-10-23 Taisho Pharmaceut Co Ltd Cold cough medicine
JP2003128549A (en) * 2001-08-15 2003-05-08 Rohto Pharmaceut Co Ltd Composition applicable to mucous membrane
JP4377564B2 (en) * 2002-05-02 2009-12-02 ロート製薬株式会社 Composition for internal use
RU2311919C2 (en) * 2002-12-30 2007-12-10 Каунсел Оф Сайнтифик Энд Индастриал Рисерч Development of anti-coughing and throat softening herbal composition
US20040202677A1 (en) * 2003-04-10 2004-10-14 Hopkins Kevin J. Method of enhanced regional body fat reduction
US20060153926A1 (en) * 2005-01-10 2006-07-13 Bascom Charles C Compositions, products and methods for controlling weight in a mammal
US20080003280A1 (en) * 2006-06-26 2008-01-03 Levine Brian M Combination cough treatment compounds and method of treating common coughs
CN100518775C (en) * 2007-03-16 2009-07-29 邓丽菊 Medicine composition for treating cough and asthma and preparation thereof

Also Published As

Publication number Publication date
CA2784214A1 (en) 2011-06-23
MX2012006625A (en) 2012-10-05
RU2012129839A (en) 2014-01-27
CO6541630A2 (en) 2012-10-16
WO2011073646A1 (en) 2011-06-23
ECSP12012132A (en) 2012-09-28
NZ600243A (en) 2013-07-26
EP2512464A1 (en) 2012-10-24
GB0921805D0 (en) 2010-01-27
CN105816462A (en) 2016-08-03
SG181686A1 (en) 2012-07-30
ZA201204293B (en) 2013-02-27
UA105944C2 (en) 2014-07-10
BR112012014161A2 (en) 2016-05-17
IL220383A0 (en) 2012-08-30
JP2013513651A (en) 2013-04-22
MX343222B (en) 2016-10-28
AU2010332494B2 (en) 2015-01-15
CA2784214C (en) 2018-01-09
PH12012501203A1 (en) 2012-11-05
RU2564904C2 (en) 2015-10-10
JP2016040279A (en) 2016-03-24
AU2010332494A1 (en) 2012-06-14
IL220383A (en) 2017-01-31
CN102740843A (en) 2012-10-17
SG10201408377QA (en) 2015-02-27

Similar Documents

Publication Publication Date Title
PE20141906A1 (en) ESKETAMINE FOR THE TREATMENT OF DEPRESSION REFRACTORY TO TREATMENT OR RESISTANT TO TREATMENT
GT201400043A (en) IMIDAZOPIRIDAZINAS REPLACED WITH AMINO
CO2017007694A2 (en) Compositions of bacillus licheniformis rti184 to benefit plant growth
MX2010014243A (en) COMPOSITION AND METHOD TO INCREASE FLUORIDE CAPTURE USING BIOACTIVE GLASS.
CR20150216A (en) COMPOSITIONS AND METHODS TO TREAT PROTEINOPATHIES
CL2008000893A1 (en) Oral care composition comprising an effective amount of a basic amino acid and an antibacterial agent; use in the antibacterial treatment of the oral cavity.
MX2011011514A (en) CANABIDIOL FORMULATIONS AND METHODS TO USE THEM.
PE20211069A1 (en) COMPOSITION INCLUDING 5'-METHYLSEELENOADENOSINE, SELENOADENOSYL-L-HOMOCYSTEIN AND GLUTAMYL-METHYLSELENOCYSTEINE RANGE
CL2013001982A1 (en) Method to reduce glucose levels and treat metabolic disorders; pharmaceutical composition comprising metformin and another antidiabetic or antiobesity agent.
AR061772A1 (en) COMPOSITION OF HIGH CONTENT OF ION FLUORIDE FOR ORAL CARE AND METHOD TO MAINTAIN ANTICARIES ACTIVITY
MX2019000547A (en) LIQUID AND LYOPHILIZED, STABILIZED FORMULATIONS OF ADAMTS13.
AR092330A1 (en) COMPOSITIONS, METHODS OF TRANSMUCOUS ABSORPTION AND TREATMENT METHOD
CR20120357A (en) COMPOSITION THAT INCLUDES A PESTICIDE AND A 2-PROPILHEPTILAMINE ALCOXYLATE
EA201200484A1 (en) PHARMACEUTICAL COMPOSITION WITH EXISTING SUBSTANCES - METHORMIN AND SYTAGLIPTIN OR VILDAGLIPTIN
CL2016000950A1 (en) Aqueous pharmaceutical composition comprising insulin glulisine and methionine; pharmaceutical kit; use in the treatment of type 1 or 2 diabetes.
CO7131352A2 (en) Topical pharmaceutical compositions
CL2015002433A1 (en) Imidazopyridazines substituted
CL2015001869A1 (en) Aqueous injectable composition of diclofenac in a solution of diethylene glycol monoethyl ether and water; Preparation method; and use in the treatment or prevention of pain and / or inflammatory conditions such as headache, sore throat, among others.
PE20121538A1 (en) THERAPEUTIC COMBINATIONS OF THEOBROMINE AND AN ANTIHISTAMINE
CO7141430A2 (en) Vesicular formulations for use in the treatment of pain or reduced mobility of a joint
EP2515912A4 (en) PHARMACEUTICAL COMPOSITION WITH VITAMIN D ANALOGON AND COLOSTERS-TENSID MIXTURE
PE20121537A1 (en) COMBINATION OF THEOBROMINE WITH A DECONGESTIVE
CO6700840A2 (en) Theobromine in combination with an expectorant or mucolytic for use in therapy
CL2012003265A1 (en) Tamarind seed polysaccharide for use in the treatment of infectious diseases; pharmaceutical and / or anti-inflammatory dermocosmetic composition containing said polysaccharide; use of a tamarind seed polysaccharide.
CO6551744A2 (en) COMBINATION OF DRUGS WITH THEOBROMINE AND ITS USE IN THERAPY

Legal Events

Date Code Title Description
FC Refusal